Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Li Li Image

      Li Li, MD,PHD

      Department of Leukemia, Division of Cancer Medicine

      Present Title & Affiliation

      Primary Appointment

      Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Dual/Joint/Adjunct Appointment

      Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2023Shanghai Jiao Tong University, Shanghai, CN, Ph.D
      2007ZhengZhou University, Zhengzhou, CN, Medicine, MD

      Postgraduate Training

      2015-2019Postgraduate Fellow, Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Experience & Service

      Editorial Activities

      Editorial board member, International Journal of Immunology, 2019 - Present

      Grant & Contract Support

      Date: 2024 - 2025
      Title:Leveraging Single-Cell Genomics to Unveil Mechanisms and Develop Novel Therapeutic Strategies for TP53 Mutant Immune Cells in AML
      Funding Source:When Everyone Survives Foundation
      Role:PI
      Date: 2023 - 2025
      Title:Multiplexed, Single‐cell Proteomic Assessment of Acute Myeloid Leukemia Proteomic Landscape in Patients Treated with CDK9 Inhibitor
      Funding Source:SELLAS Life Sciences Group, Inc
      Role:Co-I
      ID:RCTS #13052026
      Date: 2023 - 2026
      Title:Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
      Funding Source:Break Through Cancer
      Role:Key
      ID:FP00018527
      Date: 2022 - 2024
      Title:Evaluating Logic-gated CAR-NK Cells in AML
      Funding Source:SentiBio
      Role:Co-I
      ID:RCTS00060508
      Title:Targeting the CD39/CD73 Axis to Restore Immune Function and Enhance Therapeutic Outcomes in R/R Chronic Lymphocytic Leukemia
      Funding Source:Chronic Lymphocytic Leukemia Foundation
      Role:PI
      ID:FP00026562

      Selected Publications

      Peer-Reviewed Articles

      1. Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar P, Lesegretain A, Isoyama T, Seki T, Daver N, Andreeff M. Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. Clin Cancer Res 31(14):3033-3047, 2025. e-Pub 2025. PMID: 40327322.
      2. Li L, Muftuoglu M, Ayoub E, Lv J, Basyal M, Bidikian A, Zhao R, Prashant M, Mak PY, Kesharwani RK, Nishida Y, Issa GC, Varadarajan N, Carter B, Andreeff M. Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53. medRxiv, 2025. e-Pub 2025. PMID: 40297420.
      3. Huang, Y, Mohanty, V, Dede, M, Tsai, K, Daher, M, Li, L, Rezvani, K, Chen, K. Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux. Nature communications 14(1), 2023. e-Pub 2023. PMID: 37573313.
      4. Yan, ZX, Li, L, Fu, D, Wu, W, Qiao, N, Huang, Y, Jiang, L, Wu, D, Hu, Y, Zhang, HL, Xu, PP, Cheng, S, Wang, L, Lacin, S, Muftuoglu, M, Zhao, WL. Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Frontiers of Medicine 17(4):699-713, 2023. e-Pub 2023. PMID: 37060525.
      5. Li, L, Mohanty, V, Dou, J, Huang, Y, Banerjee, PP, Miao, Q, Lohr, JG, Vijaykumar, T, Frede, J, Knoechel, B, Muniz-Feliciano, L, Laskowski, TJ, Liang, S, Moyes, JS, Nandivada, V, Basar, R, Kaplan, M, Daher, M, Liu, E, Li, Y, Acharya, S, Lin, P, Shanley, M, Rafei, H, Marin, D, Mielke, S, Champlin, RE, Shpall, E, Chen, K, Rezvani, K. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Science Advances 9(30), 2023. e-Pub 2023. PMID: 37494448.
      6. Dou, J, Liang, S, Mohanty, V, Miao, Q, Huang, Y, Liang, Q, Cheng, X, Kim, SB, Choi, J, Li, Y, Li, L, Daher, M, Basar, R, Rezvani, K, Chen, R, Chen, K. Bi-order multimodal integration of single-cell data. Genome biology 23(1), 2022. e-Pub 2022. PMID: 35534898.
      7. Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, Lu J, Nunez Cortes AK, Uprety N, Ensley E, Muniz-Feliciano L, Laskowski TJ, Moyes JS, Daher M, Mendt M, Kerbauy LN, Shanley M, Li L, Lim FLWI, Shaim H, Li Y, Konopleva M, Green M, Wargo J, Shpall EJ, Chen K, Rezvani K. Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer 10(12), 2022. e-Pub 2022. PMID: 36543374.
      8. Li, Y, Basar, R, Wang, G, Liu, E, Moyes, JS, Li, L, Kerbauy, LN, Uprety, N, Fathi, M, Rezvan, A, Banerjee, PP, Muniz-Feliciano, L, Laskowski, TJ, Ensley, E, Daher, M, Shanley, M, Mendt Vilchez, MC, Acharya, S, Liu, B, Biederstädt, A, Rafei, H, Guo, X, Melo Garcia, L, Lin, P, Ang, O, Marin, D, Chen, K, Bover, L, Champlin, RE, Varadarajan, N, Shpall, E, Rezvani, K. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nature medicine 28(10):2133-2144, 2022. e-Pub 2022. PMID: 36175679.
      9. Li, L, Muftuoglu, M, Liang, S, Basyal, M, Jiangxing, LV, Akdogan, ME, Chen, K, Andreeff, M, Flowers, CR, Parmar, S. In-depth analysis of SARS-CoV-2–specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight 7(7), 2022. e-Pub 2022. PMID: 35230977.
      10. Muftuoglu, M, Li, L, Liang, S, Mak, D, Lin, AJ, Fang, J, Burks, JK, Chen, K, Andreeff, M. Extended live-cell barcoding approach for multiplexed mass cytometry. Scientific reports 11(1), 2021. e-Pub 2021. PMID: 34117319.
      11. Miao, Q, Wang, F, Dou, J, Iqbal, R, Muftuoglu, M, Basar, R, Li, L, Rezvani, K, Chen, K. Ab initio spillover compensation in mass cytometry data. Cytometry Part A 99(9):899-909, 2021. e-Pub 2021. PMID: 33342071.
      12. Kerbauy, LN, Marin, ND, Kaplan, M, Banerjee, PP, Berrien-Elliott, MM, Becker-Hapak, M, Basar, R, Foster, M, Melo, LG, Neal, CC, McClain, E, Daher, M, Nunez Cortes, AK, Desai, S, Lim, FI, Mendt Vilchez, MC, Schappe, T, Li, L, Shaim, H, Shanley, M, Ensley, E, Uprety, N, Wong, P, Liu, E, Ang, O, Cai, R, Nandivada, V, Mohanty, V, Miao, Q, Shen, Y, Baran, N, Fowlkes, NW, Chen, K, Muniz-Feliciano, L, Champlin, RE, Nieto, Y, Koch, J, Treder, M, Fischer, W, Okamoto, OK, Shpall, E, Fehniger, TA, Rezvani, K. Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates CAR-like responses against CD30+ malignancies. Clinical Cancer Research 27(13):3744-3756, 2021. e-Pub 2021. PMID: 33986022.
      13. Shaim, H, Shanley, M, Basar, R, Daher, M, Gumin, J, Zamler, D, Uprety, N, Wang, F, Huang, Y, Gabrusiewicz, KR, Miao, Q, Dou, J, Alsuliman, A, Kerbauy, LN, Acharya, S, Mohanty, V, Mendt Vilchez, MC, Li, S, Lu, J, Wei, J, Fowlkes, NW, Gokdemir, E, Ensley, E, Kaplan, M, Kassab, C, Li, L, Ozcan, G, Banerjee, PP, Shen, Y, Gilbert, AL, Jones, CM, Bdiwi, M, Nunez Cortes, AK, Liu, E, Yu, J, Imahashi, N, Muniz-Feliciano, L, Li, Y, Hu, J, Draetta, G, Marin, D, Yu, D, Mielke, S, Eyrich, M, Champlin, RE, Chen, K, Lang Jr, FF, Shpall, E, Heimberger, AB, Rezvani, K. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. Journal of Clinical Investigation 131(14), 2021. e-Pub 2021. PMID: 34138753.
      14. Liu, E, Ang, O, Kerbauy, LN, Basar, R, Kaur, I, Kaplan, M, Li, L, Tong, Y, Daher, M, Ensley, E, Uprety, N, Nunez Cortes, AK, Yang, RZ, Li, Y, Shaim, H, Reyes Silva, F, Lin, P, Mohanty, V, Acharya, S, Shanley, M, Muniz-Feliciano, L, Banerjee, PP, Chen, K, Champlin, RE, Shpall, E, Rezvani, K. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Frontiers in immunology 12, 2021. e-Pub 2021. PMID: 33717142.
      15. Daher, M, Basar, R, Gokdemir, E, Baran, N, Uprety, N, Nunez Cortes, AK, Mendt Vilchez, MC, Kerbauy, LN, Banerjee, PP, Shanley, M, Imahashi, N, Li, L, Lim, FI, Fathi, M, Rezvan, A, Mohanty, V, Shen, Y, Shaim, H, Lu, J, Ozcan, G, Ensley, E, Kaplan, M, Nandivada, V, Bdiwi, M, Acharya, S, Xi, Y, Wan, X, Mak, D, Liu, E, Jiang, XR, Ang, O, Muniz-Feliciano, L, Li, Y, Wang, J, Kordasti, S, Petrov, N, Varadarajan, N, Marin, D, Brunetti, L, Skinner, RJ, Lyu, S, Silva, L, Turk, R, Schubert, MS, Rettig, GR, McNeill, MS, Kurgan, G, Behlke, MA, Li, H, Fowlkes, NW, Chen, K, Konopleva, M, Champlin, RE, Shpall, E, Rezvani, K. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624-636, 2021. e-Pub 2021. PMID: 32902645.
      16. Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, Ozcan G, Mendt M, Hernandez Sanabria M, Kerbauy LN, Nunez Cortes AK, Li L, Banerjee PP, Muniz-Feliciano L, Acharya S, Fowlkes NW, Lu J, Li S, Mielke S, Kaplan M, Nandivada V, Bdaiwi M, Kontoyiannis AD, Li Y, Liu E, Ang S, Marin D, Brunetti L, Gundry MC, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Champlin R, Shpall EJ, Rezvani K. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv 4(14):3357-3367, 2020. e-Pub 2020. PMID: 32717029.
      17. Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv 3(23):4117-4130, 2019. e-Pub 2019. PMID: 31821460.
      18. Yan ZX, Li L, Wang W, OuYang BS, Cheng S, Wang L, Wu W, Xu PP, Muftuoglu M, Hao M, Yang S, Zhang MC, Zheng Z, Li J, Zhao WL. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. Clin Cancer Res 25(23):6995-7003, 2019. e-Pub 2019. PMID: 31444250.
      19. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 379(15):1443-1451, 2018. e-Pub 2018. PMID: 30304652.
      20. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32(2):520-531, 2018. e-Pub 2018. PMID: 28725044.
      21. Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
      22. Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161(+) T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood 129(6):740-758, 2017. e-Pub 2017. PMID: 27821506.
      23. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8:1773, 2017. e-Pub 2017. PMID: 29379494.

      Abstracts

      1. Li L. Cytomegalovirus Reactivation Shapes NK Cells Diversity Following Allogeneic Hematopoietic Stem Cell Transplantation. 58th ASH Annual Meeting and Exposition.
      2. Li L. CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo. 59th ASH Annual Meeting and Exposition.
      3. Li L. NK Cell Diversity Influences Outcomes after Cord Blood Transplantation. 59th ASH Annual Meeting and Exposition.
      4. Li L. Single-cell proteomic assessment of FLT3-ITD AML landscape identifies distinct resistance patterns. AACR-PRECISION PREVENTION, EARLY DETECTION, AND INTERCEPTION OF CANCER.
      5. Li L., Muharrem M., Edward A., Aram B., Prashant M., Jiangxing L., Mahesh B., Andrea B., Anudishi T., Amanda E., Venkata L. B., Navin V, Ghayas C. I., Michael A.. TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML. 2024 ASH annual meeting.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top